Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

<p>— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies —  — New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures — TAMPA, […]</p>
<p>The post <a href="https://forextv.com/top-news/pacira-announces-fda-approval-of-expanded-exparel-label-to-include-two-additional-nerve-block-indications/">Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>